NCT04012619 - Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2019

Primary Completion Date

November 5, 2019

Study Completion Date

December 30, 2020

Conditions

Non-squamous Non-small-cell Lung CancerAnlotinib

Interventions

DRUG

Anlotinib Hydrochloride

Patients receive pemetrexed with cisplatin/carboplatin once every 3 weeks, and anlotinib (dose escalation) once daily on days 1-14.

Trial Locations (1)

West China Hospital, Sichuan University, Chengdu